CATALYSIS Advises Molecular Diagnostic Developer Diagnoplex SA on Collaborative Agreement with Unilabs SA for the Commercialization of Colox®
CATALYSIS CAPITAL PARTNERS is pleased to announce that it acted as the exclusive financial advisor to Diagnoplex SA in connection with the signing of a collaborative agreement with Unilabs SA for the European commercialization of Colox®. Financial terms were not disclosed.
CATALYSIS Advises Orphan Oncology Company ERYTECH Pharma SA on €5.0 Million Convertible Note
CATALYSIS CAPITAL PARTNERS is pleased to announce that it acted as the exclusive financial advisor to ERYTECH Pharma SA in securing €5.0 million from Recordati in the form of a convertible note. The transaction was concurrent with ERYTECH Pharma signing a licensing and distribution agreement with Orphan Europe for GRASPA® in Europe. Orphan Europe is […]
CATALYSIS Advises Microdialysis Pioneer Dipylon Medical AB on the Sale of its Eirus Medical business unit to MAQUET, part of GETINGE GROUP
CATALYISS CAPITAL PARTNERS is pleased to announce that it acted as the exclusive financial advisor to Dipylon Medical AB on the sale of its Eirus Medical business unit assets to MAQUET, part of GETINGE GROUP. Financial terms were not disclosed.
CATALYSIS Advises Disposable Point-of-Care Diagnostic Developer Molecular Vision Ltd. on Sale of Controlling Equity Stake to Abingdon Health
CATALYSIS CAPITAL PARTNERS is pleased to announce that it acted as the exclusive financial advisor to Molecular Vision Ltd. on the sale of a controlling equity stake to Abingdon Health Ltd. Financial terms were not disclosed.